欢迎来到购物商城!
营业时间:8.00-18.00 Mon-Sat
Tel +1 2258007666 Email: rxchina@protonmail.com
Close 关闭
香港HongKong Kowloon bay
Tel +1 2258007666 Email: rxchina@protonmail.com
营业时间:8.00-18.00 Mon-Sat

Finpecia -非那雄胺

$48.00

Finpecia (Finasteride) is used to treat male pattern hair loss. Safety and efficacy have been successfully demonstrated in men between the ages of 18 to 41 years with mild to moderate hair loss. This medication is also used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

非那雄胺 用于治疗男性型脱发。在轻度至中度脱发的18至41岁之间的男性中,安全性和疗效已得到成功证明

Category: Product ID: 2866

Description

Finpecia (Finasteride) is used to treat male pattern hair loss. Safety and efficacy have been successfully demonstrated in men between the ages of 18 to 41 years with mild to moderate hair loss. This medication is also used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Finpecia Tablets – Dosage

Take one tablet of Finpecia 1 mg orally once a day, or as directed by your doctor. This medicine may be taken with or without meals.
For maximum benefit, take Finpecia pills regularly once a day. Finpecia usually must be taken regularly for 3 months for the benefits to be noticeable. Once treatment is discontinued within this duration, any gain in hair quantity will be lost within 12 months.

Drug Class and Mechanism

Finpecia prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. DHT is involved in the development of benign prostatic hyperplasia (BPH) and hair loss. This medication is used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

Missed Dose

If you miss a dose of Finpecia and you are using it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not take 2 doses at once.

Storage Instructions for Finpecia Tablets

Store at room temperature. Keep away from sunlight and moisture. Keep out of reach of children and pets.

Warnings and Precautions when using Finpecia Tablets

Before taking Finpecia, tell your doctor if you have ever had an allergic reaction to this medication, or to a similar medicine called dutasteride (Avodart). Finpecia should never be taken by a woman or a child. Finpecia can be absorbed through the skin, and women or children should not be permitted to handle Finpecia tablets. Although Finpecia is not for use by women, this medication can cause birth defects if a woman is exposed to it during pregnancy. Finpecia tablets should not be handled by a woman who is pregnant or who may become pregnant. If a woman accidentally comes into contact with this medication from a broken or crushed tablet, wash the area with soap and water right away. Call your doctor at once if you notice any breast lumps, pain, nipple discharge, or other breast changes. These may be signs of male breast cancer

 

Finpecia(Finasteride)用于治疗男性型脱发。在轻度至中度脱发的18至41岁之间的男性中,安全性和疗效已得到成功证明。该药物还用于治疗前列腺肥大的男性的良性前列腺增生(BPH)症状

保法止服用方法与劑量

推荐剂量为每天1次,1次1片, 1毫克,可与或者不与食物同服。一般在连续用药三个月或更长的时间才能观察到头发生长增加,头发数目增加或防止继续脱发的效果。建议持续用药以取得最大疗效,停止用药后疗效可在12个月发生逆转。

保法止的副作用

本品一般耐受性良好,不良反应通常轻微,一般不必终止治疗。在多例男性患者参加的一系列临床研究中对保法止的安全性进行了评价。在3项为期12个月,由多个研究中心参加,安慰剂对照的双盲研究中,本品治疗的安全性和安慰剂相似。接受保法止治疗的945例男性患者有1.7%因不良反应而终止治疗,用安慰剂的934例男性患者则有2.1%因不良反应而中止治疗。在这些研究中,接受保法止治疗的男性患者有超过1%的出现下列与用药有关的不良反应:性欲减退(保法止1.8%,安慰剂1.3%)以及阳痿(保法止1.3%,安慰剂0.7%)。此外,接受保法止治疗的男性患者有0.8%出现射精量减少。中止保法止治疗后这些不良反应消失,也有许多患者在继续用药过程中这些不良反应自行消失。另一项研究中检测了非那雄胺对射精量的影响,发现与安慰剂无差异。 在使用非那雄胺5年的病人中,观察到的上述不良反应发生率减少。上市后报告的不良事件如下:射精异常、乳房触痛或肿大、过敏反应(包括皮疹、瘙痒、荨麻疹和口唇肿胀)和睾丸疼痛。 提示:在使用保法止治疗男性型脱发时,应放松心情,减少心理负担。出现不适症状时及时联系医生,科学治疗脱发。

注意事項

本品仅用于男性患者,妊娠或可能怀孕的妇女不得接触破损或压碎的药品。非那雄胺可经过皮肤或黏膜吸收而影响男性胎儿的发育。用药前请按照医生的要求做身体检查,排除其他泌尿系统疾病或前列腺癌的可能;用药期间请听从医生的建议,定期进行前列腺癌的监测。如果您是50岁以上患者,可以1年进行1次。非那雄胺会降低血清前列腺特异抗原(PSA)的水平,在进行前列腺癌的检查前请您告知医生正在服用本药。如果您是良性前列腺增生的病人,建议您日常坚持清淡饮食、戒烟戒酒,适量饮水、不要憋尿,避免久坐,并进行一些力所能及的户外活动与锻炼。用药期间若感觉症状加重或出现异常变化,请您及时就医。

规格:100粒/一盒  1毫克

Reviews

There are no reviews yet.

Be the first to review “Finpecia -非那雄胺”

Your email address will not be published. Required fields are marked *